IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-28517-z.html
   My bibliography  Save this article

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Author

Listed:
  • Simeng Lin

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Nicholas A. Kennedy

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Aamir Saifuddin

    (St Marks Hospital and Academic Institute
    Imperial College London)

  • Diana Muñoz Sandoval

    (Imperial College London)

  • Catherine J. Reynolds

    (Imperial College London)

  • Rocio Castro Seoane

    (Imperial College London)

  • Sherine H. Kottoor

    (Imperial College London)

  • Franziska P. Pieper

    (Imperial College London)

  • Kai-Min Lin

    (Imperial College London)

  • David K. Butler

    (Imperial College London)

  • Neil Chanchlani

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Rachel Nice

    (University of Exeter
    Royal Devon and Exeter NHS Foundation Trust)

  • Desmond Chee

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Claire Bewshea

    (University of Exeter)

  • Malik Janjua

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Timothy J. McDonald

    (Royal Devon and Exeter NHS Foundation Trust)

  • Shaji Sebastian

    (Hull University Teaching Hospitals NHS Trust
    University of Hull)

  • James L. Alexander

    (Imperial College London
    Imperial College Healthcare NHS Trust)

  • Laura Constable

    (Imperial College London)

  • James C. Lee

    (Royal Free London NHS Foundation Trust
    The Francis Crick Institute
    University of Cambridge)

  • Charles D. Murray

    (Royal Free London NHS Foundation Trust)

  • Ailsa L. Hart

    (St Marks Hospital and Academic Institute)

  • Peter M. Irving

    (Guy’s and St Thomas’ NHS Foundation Trust
    King’s College London)

  • Gareth-Rhys Jones

    (Western General Hospital, NHS Lothian
    The Queen’s Medical Research Institute, The University of Edinburgh)

  • Klaartje B. Kok

    (Royal London Hospital, Barts Health NHS Trust
    Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London)

  • Christopher A. Lamb

    (Newcastle upon Tyne Hospitals NHS Foundation Trust
    Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University)

  • Charlie W. Lees

    (Western General Hospital, NHS Lothian
    Institute of Genetic and Molecular Medicine, University of Edinburgh)

  • Daniel M. Altmann

    (Imperial College London)

  • Rosemary J. Boyton

    (Imperial College London
    Royal Brompton Hospital and Harefield Hospitals)

  • James R. Goodhand

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

  • Nick Powell

    (Imperial College London
    Imperial College Healthcare NHS Trust)

  • Tariq Ahmad

    (Royal Devon and Exeter NHS Foundation Trust
    University of Exeter)

Abstract

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations are lower and half-lives shorter in patients treated with infliximab than vedolizumab, following two doses of BNT162b2 (566.7 U/mL [6.2] vs 4555.3 U/mL [5.4], p

Suggested Citation

  • Simeng Lin & Nicholas A. Kennedy & Aamir Saifuddin & Diana Muñoz Sandoval & Catherine J. Reynolds & Rocio Castro Seoane & Sherine H. Kottoor & Franziska P. Pieper & Kai-Min Lin & David K. Butler & Nei, 2022. "Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28517-z
    DOI: 10.1038/s41467-022-28517-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-28517-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-28517-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28517-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.